The global cold pain therapy market size is estimated to reach USD 3.12 billion by 2030, expanding at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidence of orthopedic diseases has led to high growth of the market. CDC estimated that nearly 78 million people in the U.S., aged 18 years or above, are expected to be diagnosed with arthritis by 2040.
Rising number of road accidents and traumatic injuries is leading to a high growth of the market. According to WHO data, every year nearly 10 million people suffer injuries in road accidents or incur a disability as a result of injuries in head, chest, arms, and legs. Thus, with the increasing number of road accidents, the demand for therapy products for pain management is rising. Increasing number of sports injuries also play a pivotal role in the rising demand for these products. The most common types of sport injuries are dislocated joints, muscle sprains & strains, tear of ligaments & tendons that hold the joints together, and fractured bones, including the vertebrae.
Geriatric population is a significant target population driving the market. Countries such as Germany and China have high geriatric population base. This factor is contributing to market growth. According to CDC, 1 in every 4 adults are affected by osteoarthritis. Thus, rising geriatric population is expected to increase the demand for cold pain therapy products.
Request a free sample copy or view report summary: Cold Pain Therapy Market Report
OTC products dominated the market in 2024 due to affordability and easy availability of products such as creams, gels, sprays, and roll-ons
The sports medicine segment is expected to witness a significant growth during the forecast period due to increasing number of sport-related injuries
Retail pharmacies accounted for a considerable revenue share in 2024, owing to increase in their demand due to easy availability of products
Among all distribution channels, e-commerce is expected to grow at the highest CAGR during the forecast period, owing to lucrative offers and discounts available online
North America dominated the cold pain therapy market in 2018 due to factors such as an increase in the prevalence of orthopedic disorders and presence of key market players in the region
Asia Pacific is likely to grow at a high rate over the forecast period due to rising geriatric population, coupled with growing healthcare awareness in the region
Orthopedic conditions led the market and accounted for a share of 49.9% in 2024 owing to rising prevalence of various musculoskeletal and joint disorders, such as osteoarthritis
Some of the major companies in the market are Beiersdorf; Breg, Inc.; DJO Global; Hisamitsu Pharmaceutical Co., Inc.; Johnson & Johnson; and Össur Corporate.
Grand View Research has segmented the global cold pain therapy market based on product, application, distribution channel, and region:
Cold Pain Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)
OTC Products
Gels, Ointments & Creams
Sprays & Foams
Patches
Roll-ons
Cold Packs
Others
Prescription Products
Motorized Devices
Non-motorized Devices
Cold Pain Therapy Application Outlook (Revenue, USD Million, 2018 - 2030)
Orthopedic Conditions
Post-operative Therapy
Sports Medicine
Post-trauma Therapy
Cold Pain Therapy Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
E-commerce
Cold Pain Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Cold Pain Therapy Market
Beiersdorf
Breg, Inc.
DJO Global (Enovis Corporation)
Johnson & Johnson Services, Inc.
Össur
Performance Health
ROHTO Pharmaceutical Co.,Ltd.
Romsons Group of Industries
Medline Industries, LP.
Unexo Life Sciences Pvt. Ltd.
"The quality of research they have done for us has been excellent..."